Neurana Pharmaceuticals

📍 San Diego, United States🗓 Founded 2013👥 9 employees💰 Last funded May 2018
Biotechnology🌐 neuranapharma.com
Website LinkedIn
Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 to focus on central nervous system (CNS) diseases and disorders. Neurana's first drug candidate is tolperisone, which has been shown to be an effective treatment for muscle spasms and spasticity and is commercialized in markets outside of the United States. Clinical studies and commercial usage have shown that tolperisone is safe and efficacious, and that the drug is non-sedating and non-addictive. In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital and MagnaSci Ventures.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Neurana Pharmaceuticals?
Neurana Pharmaceuticals has 2 investors on record on gritt.io, 2 mid-stage.
When did Neurana Pharmaceuticals last raise funding?
The most recent investment in Neurana Pharmaceuticals recorded on gritt.io was in May 2018.
When was Neurana Pharmaceuticals founded?
Neurana Pharmaceuticals was founded in 2013.
What industry is Neurana Pharmaceuticals in?
Neurana Pharmaceuticals operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Neurana Pharmaceuticals based?
Neurana Pharmaceuticals is headquartered in San Diego, United States.